Fuzeon Related Published Studies
Well-designed clinical trials related to Fuzeon (Enfuvirtide)
Adherence to enfuvirtide and its impact on treatment efficacy. [2008.02]
A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study). [2008]
Short communication safety, tolerability and pharmacokinetics of enfuvirtide administered by a needle-free injection system compared with subcutaneous injection. [2008]
Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration. [2006.12]
Viral Decay Dynamics in HIV-Infected Patients Receiving Ritonavir-Boosted Saquinavir and Efavirenz With or Without Enfuvirtide: A Randomized, Controlled Trial (HIV-NAT 012). [2006.11.01]
HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. [2006.07.15]
Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. [2006.05]
A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide. [2006]
Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients. [2006]
Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). [2006]
A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. [2006]
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. [2005.12.01]
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. [2005.12.01]
Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen. [2004.09.01]
[Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1] [2004.09]
Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. [2004.06]
Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. [2004.02]
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. [2003.08]
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. [2003.05.29]
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. [2003.05.29]
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. [2002.07.01]
Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition. [2002.07]
Well-designed clinical trials possibly related to Fuzeon (Enfuvirtide)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. [2008.07.24]
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. [2007.07.07]
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. [2007.07.07]
Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA. [2007.05]
Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. [2007.01.11]
Prognostic staging of extensively pretreated patients with advanced HIV-1 disease. [2005.11]
Subcutaneous injection survey: psychometric evaluation of a treatment satisfaction instrument associated with a novel HIV medication. [2002.09]
Other research related to Fuzeon (Enfuvirtide)
A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study. [2008.09.08]
Reassessment of enfuvirtide's role in the management of HIV-1 infection. [2008.09]
HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide. [2008.09]
Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide. [2008.08.15]
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. [2008.08]
Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. [2008.06.19]
An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS). [2008.06]
Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations. [2008.06]
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. [2008.05.16]
Immunologic benefits of enfuvirtide in patients enrolled in a drug assistance program. [2008.05]
Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function. [2008.03.01]
Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients. [2008.03]
Patients' perception and effectiveness of a treatment containing enfuvirtide when used in HIV-infected patients without very advanced disease. [2008.03]
Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. [2008]
Does iatrogenic scleroderma due to injection-site reaction to enfuvirtide impair absorption of the drug? [2008]
Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy. [2007.11.30]
Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivo. [2007.10.01]
gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure. [2007.10]
A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration. [2007.10]
Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. [2007.09.12]
Virological fitness of HIV in patients with resistance to enfuvirtide. [2007.09.12]
Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy. [2007.09]
Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. [2007.09]
The safety and efficacy of enfuvirtide therapy for HIV infection in patients with hemophilia: a case series. [2007.08.15]
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. [2007.08]
Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. [2007.07.31]
Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide. [2007.07]
Cost-effectiveness analysis of enfuvirtide (ENF) added to an optimized therapy compared with an optimized therapy in patients with HIV/AIDS. [2007.07]
Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment. [2007.04]
Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients. [2007.03.26]
Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. [2007.02.01]
[Spanish recommendations for proper use of enfuvirtide.] [2007.02]
Increased polymorphism in the HR-1 gp41 env gene encoding the enfuvirtide (T-20) target in HIV-1 variants harboring multiple antiretroviral drug resistance mutations in the pol gene. [2007.01.01]
Virologic and immunologic impact and durability of enfuvirtide-based antiretroviral therapy in HIV-infected treatment-experienced patients in a clinical setting. [2007.01]
Quality of life and tolerability after administration of enfuvirtide with a thin-walled needle: QUALITE Study. [2007.01]
[Enfuvirtide: the first step for a new strategy of antiretroviral therapy] [2007]
Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. [2006.10.24]
A cohort study of enfuvirtide immunological and virological efficacy in clinical practice. [2006.10]
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. [2006.10]
Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients. [2006.10]
Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide. [2006.09.11]
Enfuvirtide: patient acceptance and strategies for managing injection-site reactions. [2006.09]
Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations. [2006.09]
Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. [2006.09]
Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. [2006.09]
Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro. [2006.08]
Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). [2006.03.21]
Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. [2006.03.15]
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations. [2006.03]
Immunological basis for IgE hyper-production in enfuvirtide-treated HIV- positive patients. [2006.03]
Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. [2006.03]
Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects. [2006.02.14]
A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20). [2006]
Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study. [2006]
Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir. [2006]
Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. [2005.12]
[Enfuvirtide: first drug of a new family of antiretroviral agents] [2005.11]
Enfuvirtide for nurses: answering patient questions on activity, safety, and lifestyle impact. [2005.09]
Bioanalytical method development and validation for a large peptide HIV fusion inhibitor (Enfuvirtide, T-20) and its metabolite in human plasma using LC-MS/MS. [2005.07.01]
Enfuvirtide, the first fusion inhibitor to treat HIV infection. [2005.07]
Enfuvirtide is active against HIV type 1 group O. [2005.06]
Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. [2005.05.01]
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. [2005.04.01]
Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy. [2005.03]
[The role of a novel antiretroviral class (fusion inhibitors) in the treatment of advanced HIV infection. Preliminary experience with enfuvirtide] [2005.03]
Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients. [2005.03]
Enfuvirtide nursing guidelines: a report from the Association of Nurses in AIDS Care Expert Panel on Enfuvirtide. [2005.03]
Enfuvirtide: the first HIV fusion inhibitor. [2005.03]
[Fuzeon, first of the so-called "fusion inhibitor" drug in new class of AIDS treatments and its warnings] [2005.01]
[Enfuvirtide, mechanism of action and pharmacological properties] [2005]
Enfuvirtide: a review of its use in the management of HIV infection. [2005]
Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. [2005]
|
